This company has been marked as potentially delisted and may not be actively trading. NASDAQ:CHFS Nuwellis (CHFS) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock AnalysisCompetitorsTrendsBuy This Stock About Nuwellis Stock (NASDAQ:CHFS) 30 days 90 days 365 days Advanced Chart Get Nuwellis alerts:Sign Up Key Stats Today's Range$13.21▼$16.3650-Day Range$3.53▼$6.0252-Week Range$4.86▼$37.50Volume841,954 shsAverage Volume467,323 shsMarket Capitalization$95.14 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview Nuwellis, Inc. operates as a medical device company. It engages in the provision of products for the treatment of fluid overload. The firm's products include Aquadex FlexFlow System, which provides an ultrafiltration for the removal of salt and water in patients with hypervolemia, or fluid overload. It operates through Cardiac and Coronary Disease Products segment. The company was founded by Crispin Marsh and William S. Peters in November 1999 and is headquartered in Eden Prairie, MN. Read More Receive CHFS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Nuwellis and its competitors with MarketBeat's FREE daily newsletter. Email Address CHFS Stock News HeadlinesNuwellis Appoints John L. Erb as CEOJuly 2, 2025 | tipranks.comNuwellis, Inc. Reports Modest Growth and Strategic ExpansionMay 13, 2025 | tipranks.comNew crypto laws coming. Will you win or lose?Washington’s first-ever “Crypto Week” could trigger a major Bitcoin surge — but one trader says don’t just buy and hold. Larry Benedict’s “Bitcoin Skimming” strategy is built to extract 6x, 9x, or even 22x more profit from the same Bitcoin moves. He’s revealing exactly how it works in a free video.July 18 at 2:00 AM | Brownstone Research (Ad)Nuwellis Enters Agreement with Kluge Design for AquadexMay 12, 2025 | tipranks.comNuwellis Highlights Strategic Shift to Critical CareApril 3, 2025 | tipranks.comNuwellis, Inc. Earnings Call: Mixed Results with Promising ProspectsMarch 12, 2025 | tipranks.comNuwellis, Inc.: JACC: Heart Failure Paper Reports Promising Findings of Aquadex Therapy in Updated AVOID-HF Study AnalysisFebruary 22, 2025 | finanznachrichten.deNuwellis (NASDAQ:NUWE) Stock Quotes, Forecast and News SummaryOctober 2, 2024 | benzinga.comSee More Headlines CHFS Stock Analysis - Frequently Asked Questions How were Nuwellis' earnings last quarter? Nuwellis, Inc. (NASDAQ:CHFS) announced its earnings results on Monday, March, 1st. The company reported ($1.57) earnings per share for the quarter, beating the consensus estimate of ($1.91) by $0.34. The firm earned $2.04 million during the quarter. Nuwellis had a negative trailing twelve-month return on equity of 173.61% and a negative net margin of 254.26%. When did Nuwellis' stock split? Shares of Nuwellis reverse split on the morning of Friday, October 13th 2017.The 1-20 reverse split was announced on Thursday, October 12th 2017. The number of shares owned by shareholders was adjusted after the market closes on Thursday, October 12th 2017. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split. What other stocks do shareholders of Nuwellis own? Based on aggregate information from My MarketBeat watchlists, some other companies that Nuwellis investors own include Tonix Pharmaceuticals (TNXP), T2 Biosystems (TTOO), Biocept (BIOC), VBI Vaccines (VBIV), Prima BioMed (IMMP), NightHawk Biosciences (NHWK) and Sorrento Therapeutics (SRNE). Company Calendar Last Earnings3/01/2021Today7/18/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Electromedical Equipment Sub-IndustryN/A Current SymbolNASDAQ:CHFS Previous SymbolNASDAQ:SSH CIK1506492 Webwww.chf-solutions.com Phone(952) 345-4200FaxN/AEmployees66Year FoundedN/AProfitability EPS (Trailing Twelve Months)($279.28) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$18.11 million Net Margins-254.26% Pretax MarginN/A Return on Equity-173.61% Return on Assets-131.01% Debt Debt-to-Equity RatioN/A Current Ratio6.87 Quick Ratio5.97 Sales & Book Value Annual Sales$5.51 million Price / Sales17.27 Cash FlowN/A Price / Cash FlowN/A Book Value$12.79 per share Price / Book1.23Miscellaneous Outstanding Shares6,037,000Free FloatN/AMarket Cap$95.14 million OptionableNot Optionable Beta1.55 5G Stocks: The Path Forward is ProfitableEnter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free Report This page (NASDAQ:CHFS) was last updated on 7/18/2025 by MarketBeat.com Staff From Our PartnersElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredThis Could Be the Most Profitable Season of Your LifeInstitutional money is pouring in. Bitcoin ETFs are live. Altcoin adoption is accelerating. This is the sam...Crypto Swap Profits | SponsoredNew crypto laws coming. Will you win or lose?Washington’s first-ever “Crypto Week” could trigger a major Bitcoin surge — but one trader says don’t just buy...Brownstone Research | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredCritical AI announcement set to ignite AI 2.0 I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredI was wrong about TrumpI made a mistake. A mistake I feel very foolish about. After speaking with Donald Trump and some of his ...Porter & Company | Sponsored“All the land that you see I will give to you and your offspring forever…”“This land I will give to you…” — a 4,000-year-old line from Genesis may hold the key to unlocking a $150 tril...Paradigm Press | SponsoredGoogle did what!?!?A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Nuwellis, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Nuwellis With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.